# EDGAR Filing Document

**Accession Number:** 0001759186
**File Stem:** 0001683168-26-002726
**Filing Date:** 2026-4
**Character Count:** 12195
**Document Hash:** ccc3f29604197f6e517bd1bab0b99576
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-002726.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001683168-26-002726

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260407

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260407

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coeptis Therapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001759186
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 981465952
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39669
- **FILM NUMBER:** 26846322

**BUSINESS ADDRESS:**
- **STREET 1:** 105 BRADFORD ROAD, SUITE 420
- **CITY:** WEXFORD
- **STATE:** PA
- **ZIP:** 15090
- **BUSINESS PHONE:** 724-934-6467

**MAIL ADDRESS:**
- **STREET 1:** 105 BRADFORD ROAD, SUITE 420
- **CITY:** WEXFORD
- **STATE:** PA
- **ZIP:** 15090

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bull Horn Holdings Corp.
- **DATE OF NAME CHANGE:** 20181115

?xml version='1.0' encoding='ASCII'? COEPTIS THERAPEUTICS HOLDINGS, INC. 8-K

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**_____________________**

**FORM 8-K**

**_____________________**

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

Date of Report (Date of Earliest Event Reported): **April 7, 2026**

**_____________________**

**COEPTIS THERAPEUTICS HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39669** | **98-1465952** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |
| **105 Bradford Rd, Suite 420**<br> **Wexford, Pennsylvania** |  | **15090** |
| (Address of principal executive offices) |  | (Zip Code) |

---

**<u>724-934-6467</u>**

(Registrant's telephone number, including area code)

____________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br> Symbol(s) | Name of each exchange<br> on which registered |
| **Common Stock, par value $0.0001 per share** | **COEP** | **Nasdaq Capital Market** |
| **Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share** | **COEPW** | **Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp; ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;&nbsp;&nbsp;&nbsp; ☐

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events** |

---

On April 7, 2026, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis") issued a press release announcing that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger with the Company and Z Squared Inc., the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". A copy of the press release is included with the Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **<u>Exhibit No</u>.** | **<u>Description</u>** |

---

99.1 [Press Release, dated April 7, 2026](coeptis_ex9901.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Coeptis Therapeutics Holdings, Inc. | Coeptis Therapeutics Holdings, Inc. |
| Date: April 7, 2026 | By: | /s/ David Mehalick |
|  |  | David Mehalick<br> Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application**

***~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~***

WEXFORD, Pa., April 7, 2026 -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and the Company will change its corporate name to Z Squared Inc.

The new listing application approval follows the satisfaction of other key closing conditions to the proposed merger, including effectiveness of the Company's registration statement on Form S-4 (File No. 333-288329) and shareholder approval of the merger proposals at the Company's January 30, 2026 stockholders' meeting. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis, and the Company will change its corporate name to Z Squared Inc.

The transaction remains subject to satisfaction of any remaining customary closing conditions, and there can be no assurance that such conditions will be satisfied. The transaction is expected to close in Q2 2026.

**About Coeptis**:

COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.

The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.

Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.

Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com.

**About Z Squared**:

Z Squared is a digital infrastructure company focused on securing the Dogecoin (DOGE) and Litecoin (LTC) networks through institutional-scale mining operations. Upon closing of the merger, Z Squared is expected to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa, making it the largest publicly-traded pure-play Dogecoin miner in the United States.

Z Squared's operational model emphasizes efficiency, discipline, and risk management. Mined assets are converted to USD or stablecoins typically within 24 hours, aligning with a cash-flow-focused strategy rather than speculative holding. The company is led by an experienced team with deep expertise in cryptocurrency mining operations and infrastructure management.

**Participants in the Solicitation** 

Coeptis, Z Squared Inc. and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis' and Z Squared's stockholders with respect to the proposed Transaction. Investors and securityholders may obtain more detailed information regarding the names and interests in the Transaction of the directors and officers of each of Coeptis and Z Squared in the proxy statement/prospectus for the proposed Transaction as filed with the SEC, including the Registration Statement.

**No Offer or Solicitation** 

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed Transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

**Cautionary Note Regarding Forward-Looking Statements** 

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Coeptis' filings with the U.S. Securities and Exchange Commission, including the Registration Statement, which are available for review at www.sec.gov. Neither Coeptis nor Z Squared undertake any obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.

**Investor Relations Contacts**:

IR@coeptistx.com

ZSQR@mzgroup.us